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Summary
 
The nature of the CD8
 
1
 
 T cells that underlie antiviral protective immunological memory in
vivo is unclear. We have characterized peptide-specific CD8
 
1
 
 T lymphocytes directly ex vivo
from peripheral blood in humans with past exposure to influenza virus, using single cell inter-
feron 
 
g
 
 (IFN-
 
g
 
) release as a measure of effector function. In individuals in the memory state
with respect to influenza virus infection, unrestimulated antigen-specific CD8
 
1
 
 T cells dis-
played IFN-
 
g
 
 release within 6 h of antigen contact, identifying a population of memory CD8
 
1
 
T cells that exhibit effector function without needing to divide and differentiate over several
days. We have quantified circulating CD8
 
1
 
 effector T cells specific for six different MHC class
I–restricted influenza virus epitopes. Enumeration of these CD8
 
1
 
 T cells gives frequencies of
peptide-specific T cells that correlate with, but are in general severalfold higher than, CTL pre-
cursor frequencies derived from limiting dilution analysis, indicating that this novel population
of memory CD8
 
1
 
 T cells has hitherto been undetected by standard means. The phenotype of
these cells, which persist at a low frequency long after recovery from an acute viral infection,
suggests that they play a role in protective immunological memory.
 
A
 
fter recovery from an acute viral infection, the fre-
quency of antigen-specific CD8
 
1
 
 T cells is too low to
permit direct analysis. Instead, assays have used antigen-
experienced T cells that have been expanded by in vitro re-
stimulation with cognate antigen, a process that may intro-
duce quantitative and qualitative biases, particularly with
respect to the activation state of the cell. It has therefore
been difficult to establish, for viral infections in humans, the
phenotype of antigen-specific memory T cells in their nat-
ural state. In particular, it remains uncertain whether anti-
viral protective immunological memory is subserved by
long-lived quiescent T cells (1–3) that must divide and dif-
ferentiate over several days to become effectors, or by cir-
culating effector T cells continuously activated either by
persisting antigen or by cross-reactive environmental anti-
gens (4, 5).
We have studied individuals previously exposed to influ-
enza virus but without acute clinical influenza, that is, indi-
viduals in the memory state with respect to influenza virus
infection. Influenza infection is well suited for the study of
CD8
 
1
 
 T cell memory. First, CD8
 
1
 
 CTLs are crucial for
host defense against influenza virus; they are important in
the clearance of intranasal virus (6, 7) and, since CTLs rec-
ognize the relatively conserved internal viral proteins (8, 9),
they cross-react between viruses of different strains which
evade neutralizing antibody through variation in surface
glycoproteins (10, 11). Second, influenza virus–specific
CTLs secrete IFN-
 
g
 
 which has direct effects on virus repli-
cation in infected cells (12) and may be more important in
vivo for protection against influenza virus than perforin- or
fas-mediated lysis (13). Examination of IFN-
 
g
 
 secretion by
antigen-specific CD8
 
1
 
 T cells is therefore expected to be
of at least as much relevance to protection as conventional
measurements of lytic activity.
We have applied a sensitive enzyme-linked immunospot
(ELISPOT)
 
1
 
 assay for single cell IFN-
 
g
 
 secretion in a novel
way to detect low frequencies of uncultured influenza pep-
tide–specific CD8
 
1
 
 T lymphocytes freshly isolated from
peripheral blood. The ELISPOT assay detects secreted cy-
tokine molecules in the immediate vicinity of the cell from
which they are derived, while still at a relatively high con-
centration; each spot in the read-out represents a ‘footprint’
of the original cytokine-producing cell. Quantitation of
these IFN-
 
g
 
 spot-forming cells (SFCs) by this technique is
highly sensitive; for influenza virus–specific CD8
 
1
 
 CTL
lines and bulk cultures, the ELISPOT assay is an order of
magnitude more sensitive than the 
 
51
 
Cr-release cytotoxicity
assay for detecting low numbers of peptide-specific CTLs
(data not shown). We have exploited this enhanced sensi-
tivity to demonstrate the presence of circulating influenza
 
1
 
Abbreviations used in this paper:
 
 ELISPOT, enzyme-linked immunospot;
LDA, limiting dilution analysis; NP, nucleoprotein; SFC, spot-forming cell.
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1
 
 Memory T Cells
 
virus–specific CD8
 
1
 
 memory T cells capable of rapid effec-
tor function, long after exposure to the virus.
 
Materials and Methods
 
Subjects.
 
Healthy adult volunteers were recruited from May
through October, during which period influenza virus does not
circulate in Britain. Subjects were HLA typed serologically by
complement-mediated lymphocytotoxicity. Molecular subtyping
for HLA-B27.05 and HLA-A2.01 was performed by amplifica-
tion refractory mutation system PCR with sequence-specific
primers as previously described (14).
 
Peptides.
 
Six MHC class I–restricted influenza epitopes were
used and are listed in Table 1. Peptides were synthesized on solid
phase on a semiautomated peptide synthesizer (Zinsser Analytical,
Frankfurt, Germany) using f-moc chemistry; purity was con-
firmed by HPLC.
 
ELISPOT Assay for Single Cell IFN-
 
g
 
 Release: Detection of Anti-
gen-specific Effectors from Freshly Isolated PBMCs.
 
96-well polyvi-
nylidene difluoride backed plates (MAIP S 45; Millipore, Bed-
ford, MA) were coated with 15 
 
m
 
g/ml of anti–IFN-
 
g
 
 mAb 1-D1K
(Mabtech, Stockholm, Sweden) overnight at 4
 
8
 
C. Plates were
then washed 6 times with RPMI-1640 and blocked with RPMI
supplemented with 
 
l
 
-glutamine, penicillin, and 10% heat-inacti-
vated pooled human AB serum (R10) for 1 h. PBMCs were sep-
arated from heparinized whole blood on LYMPHOPREP (Ny-
comed Pharma AS, Oslo, Norway), washed 3 times, and
resuspended in R10. PBMCs were added in 100 
 
m
 
l R10/well to
the precoated plates. Input cell numbers were 5 
 
3
 
 10
 
5
 
/well, in
duplicate wells. For assays performed in parallel with limiting di-
lution analyses (LDAs), duplicate wells with 5 x 10
 
5
 
 and 2.5 
 
3
 
10
 
5
 
 PBMCs/well were used.
Detection of peptide-specific T cells from freshly isolated PBMCs
is complicated by the fact that the target cells used for peptide
presentation elicit responses from T cells of other specificities.
Heterologous B cell lines (BCLs) register strong responses from al-
loreactive T cells, whereas autologous BCLs result in potent
EBV-specific responses. Allo-specific and EBV-specific responses
were circumvented by using the autologous fresh PBMCs them-
selves to present peptide. Peptides were added to a final concen-
tration of 2 
 
m
 
M. Where the cell line CIR-A2.01 was used to
present the M1 58–66 peptide to fresh PBMCs, the cell line was
prepulsed with a 2 
 
m
 
M concentration of peptide in R10 for 1 h,
and then washed 3 times.
Assays were incubated for 6 h at 37
 
8
 
C, 5% CO
 
2
 
, but some ex-
periments were run overnight (14 h) for convenience. Assays
were arrested by shaking off the contents and washing 6 times
with PBS 0.05% Tween 20 (Sigma Chemical Co., St. Louis,
MO). Next, 100 
 
m
 
l of 1 
 
m
 
g/ml of the biotinylated anti–IFN-
 
g
 
mAb 7-B6-1 biotin (Mabtech, Stockholm, Sweden) was added.
After 3 h of incubation, plates were washed six times more and a
1:1,000 dilution of streptavidin alkaline phosphatase conjugate
(Mabtech) was added to the wells and the plates incubated at
room temperature for a further 2 h. Next, wells were again washed 6
times and 100 
 
m
 
l of chromogenic alkaline phosphatase substrate
(Bio Rad Labs., Hercules, CA), diluted 1:25 with deionized wa-
ter, was added. After 30 min, the colorimetric reaction was termi-
nated by washing with tap water and plates were air dried.
 
Enumeration of IFN-
 
g
 
 SFCs. 
 
Spots were counted under mag-
nification of 20 with a stereomicroscope (Leitz GZ6; Leitz, Wetz-
lar, Germany). Only large spots with fuzzy borders were scored as
SFCs as per convention (15). Responses were considered sig-
nificant if a minimum of five SFCs were present per well, and ad-
ditionally, this number was at least twice that in negative control
wells.
 
LDAs for Peptide-specific CTL Precursors.
 
LDAs were carried
out as described (16). In brief, influenza A virus infection of fresh
PBMCs was inactivated with human serum and the cells mixed
with uninfected PBMCs to give a final concentration of 10% in-
fected cells. Replicate microcultures (24/input cell number) were
set up in 96-well round-bottomed plates, with PBMC dilutions
ranging from 1,562–200,000 cells/well. Cultures were restimu-
lated with autologous, washed, irradiated, peptide-pulsed B cells
on day 7 or 8 at a feeder to responder ratio of 1:3 and they re-
ceived 10% Lymphocult-T (Biotest AG, Dreiech, Germany) and
fresh medium then and 3–4 d later. LDAs for donors PM, JM,
and AH were assayed on day 14, and LDAs for SM and WB (11/96)
were assayed on day 18 after a further restimulation on day 14.
Split-well analysis was performed on 
 
51
 
Cr-labeled peptide-pulsed
and unpulsed autologous B cells. Equal aliquots of each resus-
pended well were assayed for cytotoxicity on respective targets.
Maximum and spontaneous release was measured for each target.
Wells were scored as positive using a threshold of 10% specific lysis.
For WB (9/96), an alternative methodology was used. Repli-
cate microcultures (30/input cell number) of responder PBMCs
were set up with 25,000 autologous, peptide-pulsed, washed, ir-
radiated feeder PBMCs. Lymphocult-T was added on days 0 and
5. On day 8, split-well analysis was performed as above, but using
heterologous HLA-A2.01–matched BCLs as targets. Wells were
scored positive if specific lysis was greater, by three standard devi-
ations, than spontaneous release.
For both methods, where the single hit kinetics of the Poisson
model were fulfilled, with negligible lysis of unpulsed targets and
a straight line relationship, the regression line was calculated by
the maximum likelihood method. The peptide-specific CTL pre-
cursor frequency was estimated from the initial responder cell
number at which 37% of the wells were negative for cytotoxicity.
 
Characterization of Effectors by Specific Cell Depletion Studies.
 
CD4
 
1
 
 and CD8
 
1
 
 T cells were depleted by 30 min of incubation
with anti-CD4 or anti-CD8 mAbs conjugated to ferrous beads
(DYNABEADS M-450; Dynal, Oslo, Norway) in 500 
 
m
 
l R10
on ice. After dilution in R10, the conjugate-coated cells were re-
moved by a magnet (Dynal). The DYNABEADS used here reli-
ably deplete 
 
.
 
99% of the target cell population. V
 
b
 
17
 
1
 
 TCR-
bearing T lymphocytes were depleted by incubating PBMCs
with the murine mAb E17.5F3 (Human T Cell Receptor Mono-
clonal Antibody Workshop, IX International Congress of Immu-
nology, San Francisco, CA, 1995) for 30 min on ice, washing
twice and then incubating with goat anti–mouse IgG mAb con-
jugated to ferrous beads (Dynal) for a further 30 min followed by
magnetic depletion. Depletion of CD45RO
 
1
 
 PBMCs was carried
out as above except that the first mAb was the murine anti-
CD45RO mAb UCHL1 (DAKO, Glostrup, Denmark). Depletion
of the CD45RO
 
1
 
 and V
 
b
 
17 TCR-bearing cells was confirmed
on a FACS
 
Ò
 
 (Becton Dickinson, Mountain View, CA).
 
Results
 
Freshly Isolated Influenza Peptide-specific CD8
 
1
 
 T Cells from
Donors Without Active Influenza Infection Display Effector
Function Within 6 h of Antigen Contact.
 
Unrestimulated
CD8
 
1
 
 T cells, freshly isolated from the peripheral blood
of donors in the memory state with respect to influenza vi-
rus, secreted IFN-
 
g
 
 within 6 h of contact with HLA class 
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I–restricted influenza peptide epitopes. Fig. 1 
 
A
 
 quantitates
CD8
 
1
 
 T cells that display effector function within 6 h of
exposure to antigen; T cells specific for the HLA-A2.01–
restricted influenza matrix epitope, M1 58-66, were de-
tected in PBMCs freshly isolated from donor SM with
HLA-A2.01. The number of IFN-
 
g
 
 SFCs did not increase
when PBMCs were incubated in the ex vivo ELISPOT as-
say for periods of time progressively longer than 6 h, up to
40 h (data not shown). Negative controls in the ELISPOT
assay were wells with PBMCs but no peptide or irrelevant
peptides from infectious agents with which the donor was
not infected. These never elicited a response as, for exam-
ple, in Fig. 1 
 
B.
 
 Using six well-defined HLA class I–restricted
influenza epitopes, we studied a panel of donors in the mem-
ory state for influenza virus infection. Out of 29 individuals
tested with epitopes restricted by their own HLA class I al-
leles, 22 had detectable influenza peptide–specific T cells
freshly isolated from peripheral blood, that rapidly secreted
IFN-
 
g
 
 on exposure to cognate peptide (Table 1). The pro-
portion of donors responding to these influenza virus epitopes
in the ex vivo ELISPOT is considerably higher than the
proportion that respond to the same epitopes in 
 
51
 
Cr-
release cytotoxicity assays with bulk culture CTLs. Experi-
ments were performed at final peptide concentrations of 2
 
m
 
M, but responses were still readily detectable when pep-
tide concentrations were titrated down to 0.02 
 
m
 
M (data not
shown).
 
Peptide-specific Effector T Cells Detected by Ex Vivo ELISPOT
Are CD8
 
1
 
 and HLA Class I Restricted.
 
Depletion of CD8
 
1
 
T cells from fresh PBMCs completely abrogated the influ-
enza peptide–specific response (Fig. 2 
 
A
 
). Conversely, de-
pletion of CD4
 
1
 
 cells did not diminish the number of
IFN-
 
g
 
 SFCs, indicating that neither CD4
 
1
 
 cells nor their
cytokine products were required for the acquisition or de-
ployment of effector function by the freshly isolated pep-
tide-specific CD8
 
1
 
 T cells (Fig. 2 
 
A
 
). Immediate effector
responses were only detected to influenza epitopes re-
stricted by the HLA class I alleles present in the particular
donor being tested; influenza peptides restricted by HLA
class I molecules not present in the donor never resulted in
IFN-
 
g
 
 SFCs, as illustrated in Fig. 2 
 
B.
 
 To confirm that the
HLA-A2.01–restricted matrix epitope, for example, was pre-
sented through HLA-A2.01, we used the class I–reduced cell
line, CIR-A2.01, which expresses only HLA-A2.01 at a
significant level, prepulsed with the peptide M1 58-66, to
present this epitope to fresh PBMCs. Despite high back-
grounds representing allo-responses to non-A2.01 MHC
molecules expressed at a low level on CIR-A2.01, peptide-
Figure 1. (A) Freshly isolated, unrestimulated, peptide-specific, mem-
ory CD81 T cells secrete IFN-g within 6 h of antigen contact. Enumera-
tion of IFN-g SFCs in a 6 h ELISPOT assay performed with freshly iso-
lated PBMC from donor SM (class I HLA haplotype: A2.01, A24; B44,
B14). The HLA-A2.01–restricted peptide M1 58–66 was used at a final
concentration of 2 mM. Mean values from duplicate wells are shown. (B)
Irrelevant peptides do not induce IFN-g SFCs. Using fresh PBMCs from
HIV-uninfected donor SC (class I HLA haplotype: A2.01, A28; B7, B14)
in a 6 h ELISPOT assay, quantitation of IFN-g SFCs shows a response
specific for the influenza HLA-A2.01–restricted peptide M1 58–66 com-
pared with no response to the HLA-A2.01–restricted peptide from the
HIV GAG protein, GAG 77-85 (SLYNTVATL).
 
Table 1.
 
Recognition of CD8
 
1
 
 Influenza Epitopes by Freshly Isolated T Cells in the ELISPOT Assay for IFN-
 
g
 
 and Corresponding
Peptide-specific T Cell Frequencies
 
Protein Sequence
MHC class I
restriction
No. of
responders
No. of
donors tested
Range of peptide-specific IFN
 
g
 
SFCs (effector frequencies)/PBMC
M1 58–66 GILGFVFTL HLA-A2.01 7 9 1/111,000–1/3,500
NP 380–388 ELRSRYWAI HLA-B8 5 7 1/67,000–1/15,000
NP 265–273 ILRGSVAHK HLA-A3 5 6 1/83,000–1/45,000
PB1 591–599 VSDGGPNLY HLA-A1 2 4 1/100,000–1/91,000
MI 128–135 ASCMGLIY HLA-B35 2 2 1/25,000–1/16,000
NP 383–391 SRYWAIRTR HLA-B27.05 1 1 1/24,000 
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specific responses to the HLA-A2.01–restricted influenza
virus matrix epitope were detected (Fig. 2 
 
C
 
).
 
Influenza Peptide-specific CD8
 
1
 
 Effector T Cells Freshly Iso-
lated from Peripheral Blood Were Not Detectable by Convention-
al 
 
51
 
Cr-release CTL Assays.
 
During acute influenza infec-
tion, expanded antigen-specific CD8
 
1
 
 effector T cells can
be detected by 
 
51
 
Cr-release cytotoxicity assays performed
with fresh uncultured PBMCs (Klenerman, P., M. Callan,
and A.J. McMichael, unpublished observations). After re-
covery, however, such ‘fresh killing’ is not observed. Our
results indicate that this may not be because effector CD8
 
1
 
T cells are absent, but rather because their numbers have
declined to a very low frequency. ELISPOT assays with
freshly isolated PBMCs from donor WB consistently de-
tected effector CD8
 
1
 
 T cells specific for the HLA-A2.1-
restricted matrix epitope M1 58–66 at eight different time
points, whereas parallel 
 
51Cr-release cytotoxicity assays
with the same PBMCs failed to give measurable specific ly-
sis on several occasions, even at effector/target ratios of
100:1 (data not shown).
The Frequency of Peptide-specific CD81 T Cells Enumerated
by Ex Vivo ELISPOT Is Higher than the Corresponding CTL
Precursor Frequency Derived by LDA. Expressing the enu-
merated IFN-g SFCs as a proportion of the input number
of fresh PBMCs gives a measure of the frequency of circu-
lating peptide-specific CD81 effectors in peripheral blood
(Table 1). We investigated whether the antigen-specific
CD81 T cells enumerated by the ex vivo ELISPOT assay
are detectable by LDA. Table 2 shows the results for several
subjects using three different influenza virus epitopes; for
each individual, the ELISPOT assay and LDA were per-
formed in parallel on PBMCs from the same blood sample.
In all but one individual, the number of specific CD81 T
cells detected by ELISPOT assay is severalfold higher than
the CTL precursor frequency generated by the correspond-
ing LDA. For donor AH, the ELISPOT assay and LDA
give similar frequencies. For the remaining five pairs of as-
says, performed in four individuals, there is a correlation
between the IFN-g SFCs in the ELISPOT and the precur-
sor frequencies estimated by LDA (r [correlation coefficient]
5 0.99), with the ELISPOT for IFN-g consistently detect-
ing higher numbers of peptide-specific CD81 T cells than
LDA. The LDA methodology used is based on that of Leh-
ner et al. (16) who measured CTL precursor frequencies
for the HLA-A2.01–restricted matrix epitope M1 58–66 in
five healthy donors. The range of CTL precursor frequen-
cies by LDA for this epitope in the three HLA-A2.01 posi-
tive donors we have studied here is 1/59,000 to 1/250,00,
which is very similar to the range of 1/54,000 to ,1/
250,000 obtained by Lehner et al. (16).
The Majority of Influenza-specific CD81 Effectors Express
CD45RO. Antigen-experienced T cells express CD-
45RO, a marker of memory phenotype (17). Fresh PBMCs
stained with anti-CD45RO antibody were magnetically
with 2 3 104 CIR-A2.01 cells prepulsed with 2 mM of the influenza
HLA-A2.01–restricted peptide M1 58–66 and washed three times. Con-
trol wells had equal numbers of peptide-unpulsed CIR-A2.01.
Figure 2. (A) Influenza virus–specific CD81 memory T cells with
rapid effector function are CD81. Freshly isolated PBMCs from donor
SC were tested against the influenza HLA-A2.01–restricted peptide M1
58–66 at a concentration of 2 mM in a 14 h ELISPOT assay before or af-
ter depletion of CD41 or CD81 cells. Input cell numbers were 5 3 105/
well predepletion, and mean values from duplicate wells are shown. (B
and C) Unrestimulated influenza virus–specific memory CD81 T cells are
HLA class I restricted. (B) Peptide epitopes restricted by HLA class I al-
leles not present in the donor, do not elicit IFN-g SFCs. Freshly isolated
PBMCs from donor SC (class I HLA haplotype: A2.01, A28; B7, B14)
were tested in an ELISPOT assay in the absence of peptide and in the
presence of the influenza HLA-A2.01–restricted peptide M1 58–66 or the
irrelevant influenza HLA-B8-restricted peptide NP 380–388, each at a
concentration of 1 mM. (C) Freshly isolated CD81 T cells recognize the
HLA-A2.01–restricted peptide M1 58–66 presented by HLA-A2.01 on
the surface of the cell line CIR-A2.01. Fresh PBMCs from donor WB
(HLA class I haplotype: A1, A2; B7, B8) were depleted of CD41 or
CD81 cells; after depletion, 3 3 105 cells were plated out per well, along863 Lalvani et al.
depleted; this maneuver greatly reduced the number of
peptide-specific IFN-g SFCs, commensurate with the 67%
depletion of CD45RO1 cells measured by FACSÒ analysis
(Fig. 3 A). Similar results were also obtained with CD81
cells specific for other epitopes.
The Ex Vivo Response of Unrestimulated CD81 T Lympho-
cytes to the HLA-A2.1–restricted M1 58–66 Epitope Is Domi-
nated by T Cells Bearing Vb171 TCRs. M1 58–66-specific
CTL clones and lines show marked conservation for usage
of the Vb17 gene segment in their TCRs (16, 18). Deple-
tion of fresh PBMCs stained with an anti-Vb17 antibody
abrogated the ex vivo ELISPOT response to the HLA-
A2.1–restricted epitope M1 58–66, indicating that usage of
the Vb17 gene segment is highly conserved amongst circu-
lating uncultured M1 58-66–specific CD81 effectors (Fig.
3 B). In contrast, the HLA-B8–restricted response to the
nucleoprotein epitope NP 380–88 in the same donor was
unaffected.
Discussion
Using a sensitive ex vivo assay, we have directly charac-
terized unrestimulated low frequency antigen-specific
CD81 memory T cells freshly isolated from peripheral
blood. In individuals in the memory state with respect to
influenza virus infection, we have demonstrated that influ-
enza-specific memory CD81 T cells circulate in a state
wherein they can display effector function within 6 h of
antigen contact. The fact that IFN-g release within 6 h was
triggered by exposure to cognate peptide alone and in the
absence of exogenous cytokines, suggests that these CD81
T cells are capable of immediate effector function in their
natural state in vivo. This novel population of CD81 T
cells thus does not conform to the conventional view of
memory T cells which require restimulation to divide and
differentiate to become effectors (1). The identification of
influenza-specific CD81 effector T cells in our donors is
remarkable given that the donors have all been exposed to
influenza in the past but none had acute influenza at the
Table 2. Peptide-specific T Cell Frequencies Enumerated by IFN-g ELISPOT and Corresponding Precursor Frequencies by LDA for
Influenza Epitopes in a Series of Individuals
Donor Epitope tested
HLA class I
restriction Sequence
Effector frequency in
PBMCs by ELISPOT
Precursor frequency 
in PBMCs by LDA
WB (9/96)* M1 58–66 HLA-A2.01 GILGFVFTL 1/15,000 1/100,000
WB (11/96)‡ M1 58–66 HLA-A2.01 GILGFVFTL 1/111,000 1/250,000
SM‡ M1 58–66 HLA-A2.01 GILGFVFTL 1/6,000 1/59,000
JM M1 58–66 HLA-A2.01 GILGFVFTL 1/77,000 1/333,000
PM NP 380–388 HLA-B8 ELRSRYWAI 1/43,000 1/200,000
AH NP 265–273 HLA-A3 ILRGSVAHK 1/45,000 1/42,000
LDAs were performed as described in Materials and Methods and assayed at 14 d of culture, except where marked. Wells were scored positive if
peptide-specific lysis was .10% above background. Spontaneous release was ,30% of maximal release for all assays, except WB (11/96) (5 40%).
*8 d LDA.
‡18 d LDA after second restimulation on day 14.
Figure 3. (A) The majority of effectors detected in the ex vivo ELISPOT
assay bear the memory-associated cell-surface marker CD45RO. Fresh PBMCs
from donor SD were depleted of CD45RO1 cells and plated out at 5 3
105/well with or without the HLA-B27.05–restricted peptide NP 383–
391. FACSÒ analysis confirmed 67% depletion of CD45RO1 CD81 T cells
from PBMCs. (B) All detectable CD81 effectors specific for the A2.01-
restricted peptide M1 58–66 bear TCRs with the Vb17 gene segment.
The ELISPOT assay was performed with freshly isolated whole PBMCs or
PBMCs depleted of Vb171 T cells; FACSÒ analysis confirmed that the CD81
Vb171 T cells initially present among whole PBMCs were depleted by 90%.
Cells were seeded at 5 3 105/well in the presence of the HLA-A2.01–re-
stricted peptide M1 58–66 or the HLA-B8–restricted peptide NP 380–388.
PBMCs were from donor WB (HLA class I haplotype: A1, A2.01; B7, B8).864 Rapid Effector Function in CD81 Memory T Cells
time of venesection and most have not experienced clinical
influenza for several years. This does not exclude the possi-
bility of a more recent subclinical infection, but even this
would have been at least 5 mo before venesection, since in-
fluenza virus stopped circulating in this region by early
April 1996 (as per records of viral isolates, Virology De-
partment, Public Health Laboratory, John Radcliffe Hospi-
tal, Oxford, UK) and most subjects were studied from Sep-
tember through mid-November. Thus, long after an acute
viral infection in humans with a nonpersistent virus, we
have identified memory CD81 T cells capable of rapid ef-
fector activity which are, in a functional sense, in a rela-
tively activated state.
During acute (19) and some persistent (20) viral infec-
tions, the frequency of circulating antigen-specific CD81
effectors is markedly raised and lytic activity can be demon-
strated in freshly isolated PBMCs (19). However, after re-
covery, such activated effector cells are not detectable in
humans. Murine studies using peripheral (mucosal, cutane-
ous, and solid organ) rather than intravenous routes of chal-
lenge with cytopathic and noncytopathic viruses have
demonstrated that antiviral protective immunity in vivo
depends upon circulating activated CTLs, capable of rapid
effector function as measured ex vivo in CTL assays with
freshly isolated PBMCs and in vivo by cytokine-mediated
foot pad swelling (4, 21, 22). These cells are similar to the
expanded populations of CD81 effector T cells found dur-
ing acute viral infections; their continued presence in a rel-
atively activated state at a low frequency after recovery is
thought to reflect ongoing low-level stimulation by persist-
ing antigen (21). We provide evidence for an analogous
population of CD81 T cells long after recovery from an
acute viral infection in humans.
Influenza virus is cytopathic and causes disease by repli-
cating (with a life cycle of 3–6 h) and causing tissue damage
at its site of entry, the nasopharyngeal mucosa. In this situa-
tion, cellular antiviral protective immunity in vivo would
require circulating, influenza-specific CD81 T cells capable
of rapid effector function; this is the phenotype displayed
by the influenza-specific CD81 T cells characterized here,
and we propose that these cells subserve protective immu-
nological memory to influenza virus infection. The almost
immediate release of IFN-g by these lymphocytes would
have rapid antiviral effects (12) acting in a paracrine fashion
on both infected and uninfected cells at mucosal surfaces.
Confirmation of this hypothesis will require the demon-
stration of a protective association of the presence of spe-
cific CD81 effectors during the next influenza pandemic
with an antigenically shifted virus that circumvents hu-
moral immunity.
Since the freshly isolated influenza-specific CD81 T cells
we have characterized are present at such low frequencies,
it is not possible to test whether they can directly lyse target
cells since this is only measurable when they constitute 0.1–1%
of the population. However, the frequency of virus-spe-
cific CD81 T cells reaches this value in HIV-infected pa-
tients and here there is a close correlation between the fre-
quency of effector IFN-g SFCs and percentage-specific
lysis in fresh ex vivo CTL assays across a range of epitopes
(Lalvani, A., G. Ogg, and A.J. McMichael, unpublished
observations). Further indirect evidence that the cells de-
fined here may be cytotoxic is provided by the experiment
illustrated in Fig. 3 B which shows that all the freshly iso-
lated IFN-g–secreting CD81 T cells specific for the HLA-
A2.01–restricted peptide M1 58–66 bear Vb171 TCRs. It
is known that CTL lines and clones specific for the M1 58–
66 influenza epitope are dominated by TCRs incorporat-
ing the Vb17 gene segment and the magnitude of peptide-
specific lysis correlates with the proportion of CD81 T cells
bearing Vb171 TCRs (16, 18). Therefore, it seems likely
that a proportion of the M1 58–66-specific IFN-g SFCs
are CTLs, and Fig. 3 B also confirms that Vb17 restriction
of the M1 58–66 response is not merely a bias introduced
by in vitro restimulation since it also defines the fresh ex
vivo response to this epitope.
The frequency of antigen-specific T cells enumerated by
ex vivo ELISPOT is generally severalfold higher than that
calculated from LDA, the traditional method for quantitat-
ing CD81 T cells. This suggests that the LDA detects only
a subset of the specific CD81 T cells quantitated by the
ELISPOT. This may be because the LDA measures only
those CTL precursors with a capacity to proliferate on anti-
genic stimulation in vitro (20); a proportion of the effectors
detected by the ELISPOT assay probably lack this prolifer-
ative potential. It would appear that these novel CD81
memory T cells capable of rapid effector function have thus
been previously overlooked by standard techniques based
on in vitro stimulation and proliferation.
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